Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI
Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI
复制标题
DOI：
10.1016/j.ejso.2020.10.006
复制
发表时间：
2021-01-01
期刊：
影响因子：
3.8
通讯作者：
Rau, Beate
中科院分区：
文献类型：
--
作者：
Brandl, Andreas;Yonemura, Yutaka;Rau, Beate
背景：胃癌的腹膜转移(PM)相对常见(17%)，且与生存不良有关。细胞减少性手术(CRS)和热疗(HIPEC)仍然是有争议的讨论，因为它已经被证明可以提高特定患者的存活率，但只有一小部分人达到了长期存活率。本研究的目的是收集和分析全球范围内长期存活的CRS和HIPEC患者的队列，以探索相关的患者特征。方法：我们进行了问卷调查，并分发给国际腹膜表面肿瘤组织(PSOGI)的所有合作者。纳入标准是：组织病理学证实的胃癌PM，接受CRS和HIPEC治疗，以及总生存期&5年。结果：从1994-2014年间收治的448例患者中，共纳入28例患者，平均年龄53.0岁，平均经皮冠状动脉介入治疗3.3岁。总的中位生存期为11.0年(最短5.0年，最长27.9年)。细胞减少率(CC-0)和经皮冠状动脉介入治疗的预测完备性
Background: Peritoneal metastasis (PM) of gastric cancer (GC) is relatively common (17%) and is associated with poor survival. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is still controversially discussed, as it has proven an increase in survival in selected patients, but only a small subgroup reached long-term survival. The aim of this study was to collect and analyse a worldwide cohort of patients treated with CRS and HIPEC with long-term survival in order to explore relevant patient characteristics.Methods: We conducted a questionnaire, which was distributed to all collaborators of the Peritoneal Surface Oncology Group International (PSOGI). Inclusion criteria were: histopathologic proven PM of GC, treated with CRS and HIPEC, and overall survival >5 years. Patient, tumour, and therapeutic details were collected and analysed.Results: From an analysis of 448 patients treated between 1994 and 2014, a total of 28 patients with a mean age of 53.0 years and mean PCI of 3.3 were included. The overall median survival was 11.0 years (min 5.0; max 27.9). The predictors completeness of cytoreduction (CC-0) and PCI